185 related articles for article (PubMed ID: 22119587)
1. Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009.
Dorell CG; Stokley S; Yankey D; Markowitz LE
Vaccine; 2012 Jan; 30(3):503-5. PubMed ID: 22119587
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with human papillomavirus vaccine-series initiation and healthcare provider recommendation in US adolescent females: 2007 National Survey of Children's Health.
Lau M; Lin H; Flores G
Vaccine; 2012 Apr; 30(20):3112-8. PubMed ID: 22425179
[TBL] [Abstract][Full Text] [Related]
3. The HPV vaccine: are dosing recommendations being followed?
Tan W; Viera AJ; Rowe-West B; Grimshaw A; Quinn B; Walter EB
Vaccine; 2011 Mar; 29(14):2548-54. PubMed ID: 21300098
[TBL] [Abstract][Full Text] [Related]
4. A randomized intervention of reminder letter for human papillomavirus vaccine series completion.
Chao C; Preciado M; Slezak J; Xu L
J Adolesc Health; 2015 Jan; 56(1):85-90. PubMed ID: 25438965
[TBL] [Abstract][Full Text] [Related]
5. Acceptance and compliance with postpartum human papillomavirus vaccination.
Wright JD; Govindappagari S; Pawar N; Cleary K; Burke WM; Devine PC; Lu YS; Tsai WY; Lewin SN; Herzog TJ
Obstet Gynecol; 2012 Oct; 120(4):771-82. PubMed ID: 22996094
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007.
Jain N; Euler GL; Shefer A; Lu P; Yankey D; Markowitz L
Prev Med; 2009 May; 48(5):426-31. PubMed ID: 19100762
[TBL] [Abstract][Full Text] [Related]
7. Age at HPV vaccine initiation and completion among US adolescent girls: trend from 2008 to 2012.
Rahman M; McGrath CJ; Hirth JM; Berenson AB
Vaccine; 2015 Jan; 33(5):585-7. PubMed ID: 25529289
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccination in female pediatric cancer survivors.
Hoffman L; Okcu MF; Dreyer ZE; Suzawa H; Bryant R; Middleman AB
J Pediatr Adolesc Gynecol; 2012 Oct; 25(5):305-7. PubMed ID: 22831900
[TBL] [Abstract][Full Text] [Related]
9. National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Aug; 61(34):671-7. PubMed ID: 22932301
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid.
Cook RL; Zhang J; Mullins J; Kauf T; Brumback B; Steingraber H; Mallison C
J Adolesc Health; 2010 Dec; 47(6):596-9. PubMed ID: 21094437
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with completion of the human papillomavirus vaccine series.
Neubrand TP; Breitkopf CR; Rupp R; Breitkopf D; Rosenthal SL
Clin Pediatr (Phila); 2009 Nov; 48(9):966-9. PubMed ID: 19483128
[No Abstract] [Full Text] [Related]
12. The accuracy of human papillomavirus vaccination status based on adult proxy recall or household immunization records for adolescent females in the United States: results from the National Immunization Survey-Teen.
Ojha RP; Tota JE; Offutt-Powell TN; Klosky JL; Ashokkumar R; Gurney JG
Ann Epidemiol; 2013 May; 23(5):281-5. PubMed ID: 23453240
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females.
Weiss TW; Zimet GD; Rosenthal SL; Brenneman SK; Klein JD
J Adolesc Health; 2010 Jul; 47(1):3-11. PubMed ID: 20547286
[TBL] [Abstract][Full Text] [Related]
14. Compliance with recommendations and opportunities for vaccination at ages 11 to 12 years: evaluation of the 2009 national immunization survey-teen.
Stokley S; Cohn A; Jain N; McCauley MM
Arch Pediatr Adolesc Med; 2011 Sep; 165(9):813-8. PubMed ID: 21893647
[TBL] [Abstract][Full Text] [Related]
15. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
[TBL] [Abstract][Full Text] [Related]
16. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
17. HPV vaccine recommendations.
Committee on Infectious Diseases
Pediatrics; 2012 Mar; 129(3):602-5. PubMed ID: 22371460
[TBL] [Abstract][Full Text] [Related]
18. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with parental intentions for male human papillomavirus vaccination: results of a national survey.
Dempsey AF; Butchart A; Singer D; Clark S; Davis M
Sex Transm Dis; 2011 Aug; 38(8):769-76. PubMed ID: 21336230
[TBL] [Abstract][Full Text] [Related]
20. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
Grant LA; Dunne EF; Chesson H; Markowitz LE
Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
